S. Richard Geary's most recent trade in Ionis Pharmaceuticals Inc was a trade of 18,300 Non-Qualified Stock Option (right to buy) done . Disclosure was reported to the exchange on Nov. 5, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Nov 2025 | 18,300 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 60.89 per share. | 05 Nov 2025 | 18,300 | 77,957 (0%) | 0% | 60.9 | 1,114,287 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 75.42 per share. | 05 Nov 2025 | 18,300 | 59,657 (0%) | 0% | 75.4 | 1,380,204 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 76.10 per share. | 05 Nov 2025 | 14,738 | 59,657 (0%) | 0% | 76.1 | 1,121,521 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 56.78 per share. | 05 Nov 2025 | 14,738 | 74,395 (0%) | 0% | 56.8 | 836,824 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Nov 2025 | 14,738 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 75.01 per share. | 05 Nov 2025 | 801 | 59,657 (0%) | 0% | 75.0 | 60,083 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 60.89 per share. | 05 Nov 2025 | 801 | 60,458 (0%) | 0% | 60.9 | 48,773 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Nov 2025 | 801 | 18,300 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 75.01 per share. | 05 Nov 2025 | 800 | 59,657 (0%) | 0% | 75.0 | 60,008 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 56.78 per share. | 05 Nov 2025 | 800 | 60,457 (0%) | 0% | 56.8 | 45,424 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Nov 2025 | 800 | 14,738 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 75.05 per share. | 03 Nov 2025 | 905 | 59,657 (0%) | 0% | 75.1 | 67,924 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Nov 2025 | 905 | 15,538 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 56.78 per share. | 03 Nov 2025 | 905 | 60,562 (0%) | 0% | 56.8 | 51,386 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 75.05 per share. | 03 Nov 2025 | 775 | 59,657 (0%) | 0% | 75.1 | 58,167 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Nov 2025 | 775 | 19,101 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 60.89 per share. | 03 Nov 2025 | 775 | 60,432 (0%) | 0% | 60.9 | 47,190 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2025 | 34,664 | 16,443 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 75.11 per share. | 31 Oct 2025 | 34,664 | 79,657 (0%) | 0% | 75.1 | 2,603,554 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 56.78 per share. | 31 Oct 2025 | 34,664 | 114,321 (0%) | 0% | 56.8 | 1,968,222 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2025 | 34,585 | 19,876 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 75.11 per share. | 31 Oct 2025 | 34,585 | 79,657 (0%) | 0% | 75.1 | 2,597,621 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 60.89 per share. | 31 Oct 2025 | 34,585 | 114,242 (0%) | 0% | 60.9 | 2,105,881 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 75.11 per share. | 31 Oct 2025 | 20,000 | 59,657 (0%) | 0% | 75.1 | 1,502,166 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 75.05 per share. | 31 Oct 2025 | 905 | 59,657 (0%) | 0% | 75.1 | 67,924 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 60.89 per share. | 31 Oct 2025 | 905 | 60,562 (0%) | 0% | 60.9 | 55,105 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2025 | 905 | 18,971 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 75.05 per share. | 31 Oct 2025 | 775 | 59,657 (0%) | 0% | 75.1 | 58,167 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 56.78 per share. | 31 Oct 2025 | 775 | 60,432 (0%) | 0% | 56.8 | 44,005 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2025 | 775 | 15,668 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 53.77 per share. | 30 Sep 2025 | 57,900 | 137,557 (0%) | 0% | 53.8 | 3,113,283 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2025 | 57,900 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 65.24 per share. | 30 Sep 2025 | 57,900 | 79,657 (0%) | 0% | 65.2 | 3,777,668 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 50.37 per share. | 02 Sep 2025 | 10,000 | 79,657 (0%) | 0% | 50.4 | 503,671 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Other type of transaction at price $ 27.71 per share. | 29 Aug 2025 | 165 | 89,657 (0%) | 0% | 27.7 | 4,572 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 42.86 per share. | 05 Aug 2025 | 10,000 | 89,492 (0%) | 0% | 42.9 | 428,593 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Other type of transaction at price $ 28.21 per share. | 28 Feb 2025 | 415 | 99,492 (0%) | 0% | 28.2 | 11,708 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2025 | 3,820 | 100,483 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 32.40 per share. | 30 Jan 2025 | 1,406 | 99,077 (0%) | 0% | 32.4 | 45,561 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 33,000 | 79,625 | - | - | Restricted Stock Unit | |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 22,000 | 64,801 | - | - | Performance Restricted Stock Units | |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2025 | 18,901 | 60,724 | - | - | Restricted Stock Unit | |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2025 | 18,901 | 103,735 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 32.86 per share. | 15 Jan 2025 | 7,072 | 96,663 (0%) | 0% | 32.9 | 232,407 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 22,000 | 22,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Other type of transaction at price $ 38.64 per share. | 30 Aug 2024 | 11 | 84,834 (0%) | 0% | 38.6 | 425 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 49.63 per share. | 28 Aug 2024 | 331 | 84,823 (0%) | 0% | 49.6 | 16,428 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 49.16 per share. | 28 Aug 2024 | 320 | 85,154 (0%) | 0% | 49.2 | 15,731 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 48.00 per share. | 05 Aug 2024 | 2,430 | 85,508 (0%) | 0% | 48 | 116,640 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | Officer Level 14 | Other type of transaction at price $ 34.43 per share. | 29 Feb 2024 | 604 | 87,938 (0%) | 0% | 34.4 | 20,793 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 50.04 per share. | 02 Feb 2024 | 1,995 | 87,300 (0%) | 0% | 50.0 | 99,836 | Common Stock |
| Ionis Pharma Inc | S. Geary Richard | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 3,820 | 89,295 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharma Inc | Richard Geary S. | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 50.04 per share. | 01 Feb 2024 | 1,961 | 87,334 (0%) | 0% | 50.0 | 98,135 | Common Stock |
| Ionis Pharma Inc | S. Richard Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jan 2024 | 19,852 | 92,813 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharma Inc | S. Geary Richard | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jan 2024 | 19,852 | 46,625 | - | - | Restricted Stock Unit | |
| Ionis Pharma Inc | Richard Geary S. | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 50.42 per share. | 16 Jan 2024 | 7,338 | 85,475 (0%) | 0% | 50.4 | 369,960 | Common Stock |
| Ionis Pharma Inc | S. Geary Richard | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2024 | 20,400 | 66,477 | - | - | Restricted Stock Unit | |
| Ionis Pharma Inc | Geary S. Richard | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2024 | 17,000 | 42,801 | - | - | Performance Restricted Stock Units | |
| Ionis Pharma Inc | S. Richard Geary | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 27,200 | 27,200 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharma Inc | Geary S. Richard | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Dec 2023 | 6,500 | 4,112 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharma Inc | Richard Geary S. | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.34 per share. | 20 Dec 2023 | 6,500 | 79,461 (0%) | 0% | 47.3 | 307,710 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 49.64 per share. | 20 Dec 2023 | 6,500 | 72,961 (0%) | 0% | 49.6 | 322,643 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 49.29 per share. | 20 Dec 2023 | 4,112 | 72,961 (0%) | 0% | 49.3 | 202,681 | Common Stock |
| Ionis Pharma Inc | S. Richard Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Dec 2023 | 4,112 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharma Inc | Richard Geary S. | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.34 per share. | 20 Dec 2023 | 4,112 | 77,073 (0%) | 0% | 47.3 | 194,662 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 49.21 per share. | 14 Dec 2023 | 6,571 | 72,961 (0%) | 0% | 49.2 | 323,381 | Common Stock |
| Ionis Pharma Inc | Richard Geary S. | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.34 per share. | 14 Dec 2023 | 6,571 | 79,532 (0%) | 0% | 47.3 | 311,071 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2023 | 6,571 | 14,654 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 50.19 per share. | 14 Dec 2023 | 4,042 | 72,961 (0%) | 0% | 50.2 | 202,856 | Common Stock |
| Ionis Pharma Inc | S. Richard Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2023 | 4,042 | 10,612 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharma Inc | Geary S. Richard | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.34 per share. | 14 Dec 2023 | 4,042 | 77,003 (0%) | 0% | 47.3 | 191,348 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Other type of transaction at price $ 30.51 per share. | 28 Feb 2023 | 575 | 72,960 (0%) | 0% | 30.5 | 17,546 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2023 | 3,822 | 74,305 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 40.66 per share. | 03 Feb 2023 | 1,920 | 72,385 (0%) | 0% | 40.7 | 78,070 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jan 2023 | 21,983 | 78,356 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jan 2023 | 21,983 | 46,077 | - | - | Restricted Stock Unit | |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 39.57 per share. | 17 Jan 2023 | 7,873 | 70,483 (0%) | 0% | 39.6 | 311,525 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2023 | 17,207 | 68,060 | - | - | Restricted Stock Unit | |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2023 | 14,338 | 25,801 | - | - | Performance Restricted Stock Units | |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 22,942 | 22,942 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Other type of transaction at price $ 28.37 per share. | 28 Feb 2022 | 621 | 56,373 (0%) | 0% | 28.4 | 17,620 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2022 | 21,391 | 50,853 | - | - | Restricted Stock Unit | |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2022 | 21,391 | 63,357 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.12 per share. | 18 Jan 2022 | 7,605 | 55,752 (0%) | 0% | 30.1 | 229,063 | Common Stock |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2022 | 15,284 | 72,244 | - | - | Restricted Stock Unit | |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2022 | 11,463 | 11,463 | - | - | Performance Restricted Stock Units | |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 30,567 | 30,567 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharma Inc | Richard S. Geary | EVP, Chief Development Offc | Other type of transaction at price $ 33.80 per share. | 31 Aug 2021 | 46 | 41,966 (0%) | 0% | 33.8 | 1,555 | Common Stock |